A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients

Clinical Trial ID NCT01155453

Rank	Title	Journal	Year	PubWeight™‹?›
1	Targeting the PI3K/Akt/mTOR pathway--beyond rapalogs.	Oncotarget	2010	2.44
2	Emerging targeted agents in metastatic breast cancer.	Nat Rev Clin Oncol	2013	1.59
3	Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.	Oncotarget	2014	1.34
4	NRAS mutant melanoma: biological behavior and future strategies for therapeutic management.	Oncogene	2012	1.15
5	KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors.	PLoS One	2012	0.96
6	Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011".	J Transl Med	2012	0.87
7	Personalized medicine in metastatic non-small-cell lung cancer: promising targets and current clinical trials.	Curr Oncol	2012	0.81
8	Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials.	Oncotarget	2014	0.78
9	Therapeutic Approaches to RAS Mutation.	Cancer J	2016	0.76
10	Phosphatidylinositol 3-Kinase: A Link Between Inflammation and Pancreatic Cancer.	Pancreas	2016	0.75